0001415889-22-012273.txt : 20221208 0001415889-22-012273.hdr.sgml : 20221208 20221208180027 ACCESSION NUMBER: 0001415889-22-012273 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221206 FILED AS OF DATE: 20221208 DATE AS OF CHANGE: 20221208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dake Benjamin T CENTRAL INDEX KEY: 0001869248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 221453346 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-12082022_061206.xml X0306 4 2022-12-06 0001798749 Aerovate Therapeutics, Inc. AVTE 0001869248 Dake Benjamin T C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SEE REMARKS Common Stock 2022-12-06 4 M 0 2412 1.74 A 2412 D Common Stock 2022-12-06 4 M 0 37588 2.14 A 40000 D Common Stock 2022-12-06 4 S 0 2011 15.6073 D 37989 D Common Stock 2022-12-06 4 S 0 1259 16.8984 D 36730 D Common Stock 2022-12-06 4 S 0 36115 17.8004 D 615 D Common Stock 2022-12-06 4 S 0 615 18.2921 D 0 D Stock Option (Right to Buy) 1.74 2022-12-06 4 M 0 905 0 D 2030-09-03 Common Stock 906 11772 D Stock Option (Right to Buy) 1.74 2022-12-06 4 M 0 1507 0 D 2030-09-03 Common Stock 1507 30136 D Stock Option (Right to Buy) 2.14 2022-12-06 4 M 0 1018 0 D 2031-04-01 Common Stock 1018 28515 D Stock Option (Right to Buy) 2.14 2022-12-06 4 M 0 36570 0 D 2031-04-01 Common Stock 36570 218030 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.152 to $15.98, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.19 to $17.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.191 to $18.16, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.192 to $18.33, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Officer Title: President, Chief Operating Officer and Secretary /s/ George A. Eldridge, Attorney-in-Fact 2022-12-08